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INTRODUCTION
Pneumonia was the fourth leading cause of mortality in South 
Korea in 2017, and Streptococcus pneumonia was the leading 
cause of bacterial pneumonia.1,2 Despite the use of antibiotics 
and intensive care over the past 50 years, the case fatality rate 
of pneumococcal bacteremia has remained at 15–20% in chil-
dren and young adults, and at 30–40% in the elderly.3-5 More-
over, the rates of antimicrobial resistance in various pneumo-
cocci have been steadily increasing. Under these circumstances, 
vaccination has become the most cost-effective way to prevent 
pneumococcal infections.6 The two main types of pneumo-
coccal vaccines are 23-valent pneumococcal polysaccharide 
vaccines (PPSVs) and pneumococcal conjugate vaccines 
(PCVs), in which polysaccharides are conjugated to a protein.7 
The National Immunization Program (NIP) of South Korea in-
troduced 23-valent PPSVs in 2013 for people aged 65 years and 
older,8 and PCVs in 2014 for children under 5 years of age.9 
The expansion of NIP appears to have benefited both children 
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and adults in recent years; in 2017, more than 2 million doses 
of pneumococcal vaccines have been administered to both 
adults and children.10 
Amidst the widespread use of pneumococcal vaccines, it 
would be interesting to analyze the difference in adverse events 
(AEs) between the two types of vaccines. While the most com-
mon adverse reactions after receiving PPSVs were local reac-
tions, such as injection-site pain (soreness, tenderness) (60%), 
local swelling or induration (20.3%), headache (17.6%), local 
erythema (16.4%), asthenia and fatigue (13.2%), and myalgia 
(6.1%), less than 1% of the recipients developed fever or more 
severe local reactions.11 In comparison, injection-site reactions 
(erythema) occurred in approximately 10% of PCV recipients, 
and there may have been an increase in milder injection-site 
reactions with subsequent doses in older age groups (12–15 
months of age).12 Overall, there was no difference between 
PCVs and PPSVs in terms of the incidence of serious adverse 
events (SAEs) reported within 1 month of an initial study dose. 
While these aforementioned studies evaluated the immunoge-
nicity and safety of PPSVs and PCVs in adults who were older 
than 65 years, these studies were limited in that they were ran-
domized clinical trials involving only 1000 older patients.13,14 
Therefore, the objective of this study is to analyze AEs after vac-
cination with different types of pneumococcal vaccines (PPSVs 
and PCVs) using a spontaneous AE reporting system, and to 
determine the signals of pneumococcal vaccines by compar-




The spontaneous AE reporting system was first introduced in 
South Korea in 1988 when the Ministry of Food and Drug 
Safety started collecting spontaneous AE reports. In 2012, the 
Korea Institute of Drug Safety and Risk Management (KIDS) 
developed the Korea Adverse Event Reporting System (KAERS) 
to facilitate computerized reporting and management of AE 
reports. 
Data on the AEs of pneumococcal vaccines were taken from 
KAERS. The KAERS database contained a total of 39933 re-
ports on AEs after vaccination with pneumococcal vaccines 
from January 2005 to December 2016. We classified all reported 
AEs into two subgroups: AEs after receiving PPSVs and those 
after receiving PCV. We then calculated the percentage of AEs 
according to vaccine type by dividing the number of AEs after 
receiving each vaccine type (i.e., PPSV and PCV) by the num-
ber of AEs after receiving all vaccines, and analyzed the tem-
poral trends of AEs according to the year from 2005 and 2016. 
We excluded cases without basic patient data, such as age.
Definition of covariates
When comparing the AEs between PPSVs and PCVs, we in-
cluded a number of covariates such as age, sex, type of report-
er, SAE, and degree of causality. Age was divided into following 
groups: children aged 0 to 18 years and adults aged ≥19 years 
for PPSVs, and only children aged 0 to 18 years for PCVs. This 
was because there was only a single case of AE after receiving 
PCVs in an adult aged over 18 years in our data. As a result, we 
could not compare AEs in adults between PPSVs and PCVs. 
Reporters of AEs were categorized into four groups: physician, 
pharmacist, nurse, and consumer. SAEs were classified into 
death and non-fatal categories. The degree of causality was 
classified into seven terms: certain, probable, possible, unlike-
ly, unclassified, unassessable, and not applicable. This catego-
rization was based on the “World Health Organization-Uppsa-
la Monitoring Centre System for standardized case causality 
assessment.”15
Coding of AEs
All drug names in the database were coded using the Ana-
tomical Therapeutic Chemical classification system, and AEs 
were coded using the World Health Organization Adverse Re-
action Terminology (WHO-ART, ver. 092). The WHO-ART, de-
veloped to serve as a terminology for coding adverse reaction 
terms, covers most medical terms needed in AE reporting. Fol-
lowing a hierarchical structure, WHO-ART uses system-organ 
classes and preferred terms as the main and sub-categories, re-
spectively. Symptoms that matched the same preferred terms 
were treated as the same event. Two or more preferred terms 
reported for one patient were counted as different vaccine AEs. 
According to the WHO criteria, SAEs were defined as one of 
three cases: fatal, causing hospitalization or persistent disability, 
and life-threatening.
Signal detection and validation
In pharmacovigilance analyses, data mining is a process of de-
tecting signals to find statistical associations and patterns be-
tween drugs and AEs in a large database. Three indicators are 
used to detect signals from spontaneously reported data: pro-
portional reporting ratio (PRR), reporting odds ratio (ROR), 
and information component (IC). PRR is the proportion of 
specific AEs for a particular vaccine divided by the proportion 
of specific AEs for other vaccines. ROR is calculated by dividing 
the odds of target AEs for patient exposure to a specific vaccine 
by those for exposure to other vaccines. For PRR and ROR, a 
signal is detected if PRR and ROR values are 2 or higher, χ2 (chi-
squared) values are 4 or higher, and the number of occurrenc-
es is 3 or greater. IC is a logarithmic metric of the value calcu-
lated by dividing the probability of target AEs associated with 
a target vaccine with the probability of all AEs associated with 
all vaccines in the database.16 It is given by a Bayesian confi-
dence propagation neural network. The IC criterion was set at 
the lower limit of 95% confidence interval greater than 0. A 
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signal was defined as the AE that met all three indices of PRR, 
ROR, and IC. 
The detected signals for each vaccine were compared with 
the information on vaccine labels in South Korea to determine 
whether the signal was listed on the vaccine label. Assuming 
the AE listed on the vaccine label is a true value, we examined 
how accurately the signal detected by data mining discrimi-
nated the known AE on the label. The detected signals were 
validated by calculating four indicators: sensitivity, specificity, 
positive predictive value, and negative predictive value. 
Statistical analysis
We calculated the frequency and percentage (%) of all categor-
ical variables. The Cochran-Mantel-Haenszel chi-squared test 
was used to compare the demographic characteristics. For test-
ing the difference in proportions, we conducted the exact two-
sided chi-squared test based on the test score.17 All variables 
were considered statistically significant if the p-value was lower 
than 0.05. SAS (Windows version 9.30, SAS Institute Inc., Cary, 
NC, USA) and Excel 2013 (Microsoft Corp., Redmond, WA, 
USA) were used to create a dataset and perform all statistical 
procedures. 
RESULTS
Among the patients vaccinated with PPSVs, females account-
ed for 62.3% (n=820) of the adult population and 44.9% (n= 
801) of the children population (Table 1). An equal number of 
male and female children was vaccinated with PCVs. Physi-
cians reported 47.9% and 80.9% of AEs in adults and children 
vaccinated with PPSVs, respectively. Moreover, 0.5% (n=6) of 
adults and 0.9% of children (n=16) died after receiving PPSVs. 
Among the patients vaccinated with PPSVs, 2.9% and 16.2% of 
AEs were unlikely to be caused in adults and children, respec-
tively; the causality of another 2.7% and 12.0% of AEs, respec-
tively, was not assessable. Among the children vaccinated 
with PCVs, 2.4% of AEs were assessed to be possible to have 
been caused by the vaccines, and the causality of another 0.4% 
and 0.0% of AEs was assessed as probable and certain, respec-
tively. Most (89.2%) of the adults who were vaccinated with 
PPSVs received only one pneumococcal vaccine, whereas 56.7% 
and 47.8% of the children who were vaccinated with PPSV 
and PCV, respectively, received another vaccine. The median 
interval between vaccination date and onset date of AEs was 
7, 320, and 532.5 days for adults and children receiving PPSVs 
and children receiving PCV, respectively.
Of all the 39933 AE reports after pneumococcal vaccination, 
5718 (14.3%) AEs were pneumococcal vaccine-related (Fig. 1). 
Injection-site reaction was the most common AE in adults 
vaccinated with PPSVs, accounting for 25.0% of all AEs. Respi-
ratory system disorders, as a category, were the most frequent 
AEs in children vaccinated with PPSVs or PCVs (Table 2). Fe-
ver occurred frequently in both children and adults vaccinat-
ed with PPSVs, accounting for 23.9% and 18.4% of AEs, re-
spectively. The most frequent AE occurring in children after 
receiving PCVs was pharyngitis (26.2%), followed by rhinitis 
(23.2%).
We summarized the AEs to compare the signals obtained 
through this study and labels in Tables 3, 4, and 5. In this study, 
signals were considered meaningful when all three criteria 
were significant. These signals were detected only in patients 
vaccinated with PPSVs. In the case of adults vaccinated with 
PPSVs, the most frequently reported AEs, such as injection-site 
reaction and fever, were labeled and represented as signals (Ta-
ble 3). However, in the case of children vaccinated with PPSVs, 
the frequently reported respiratory system disorders, such as 
pharyngitis and rhinitis, were not mentioned on the labels and 
Table 1. Demographic Characteristics of PPSV and PCV Recipients 
Whose Adverse Events Were Reported to the Korea Adverse Event 









0-18 0 (0.0) 1784 (100.0) 500 (100.0)
≥19 1317 (100.0) 0 (0.0) 0 (0.0)
Sex
Male 474 (36.0) 927 (52.0) 248 (49.6) <0.001
Female 820 (62.3) 801 (44.9) 248 (49.6) <0.001
Missing 23 (1.7) 56 (3.1) 4 (0.8) 0.002
Type of reporter
Physician 631 (47.9) 1444 (80.9) 480 (96.0) <0.001
Pharmacist 40 (3.0) 9 (0.5) 1 (0.2) <0.001
Nurse 121 (9.2) 67 (3.8) 5 (1.0) <0.001
Consumer 127 (9.6) 41 (2.3) 3 (0.6) <0.001
Other 323 (24.5) 178 (10.0) 11 (2.2) <0.001
Missing 75 (5.7) 45 (2.5) 0 (0.0) <0.001
Serious adverse event <0.001
Death 6 (0.5) 16 (0.9) 0 (0.0) 
Non-fatal 232 (17.6) 120 (6.7) 13 (2.6)
Degree of causality
Certain 91 (6.9) 71 (4.0) 0 (0.0) <0.001
Probable 146 (11.1) 65 (3.6) 2 (0.4) <0.001
Possible 316 (24.0) 105 (5.9) 12 (2.4) <0.001
Unlikely 38 (2.9) 289 (16.2) 226 (45.2) <0.001
Unclassified 93 (7.1) 96 (5.4) 27 (5.4) 0.125
Unassessable 36 (2.7) 214 (12.0) 52 (10.4) <0.001
Missing 597 (45.3) 944 (52.9) 181 (36.2) <0.001
Received one vaccine 1175 (89.2) 773 (43.3) 261 (52.2) <0.001
Median interval (days) 7� 320� 532.5
PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate 
vaccine.
Data are presented as number (%).
*Compared by Cochran-Haenszel chi-squared test.
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not detected as signals (Table 4).
A total of 13 AEs after pneumococcal vaccination met the cri-
teria of three data mining indices for signal detection. Twelve 
AEs reported for adults vaccinated with PPSVs satisfied all 
three indices for signal detection; three AEs (hypotension, sep-
sis, and apathy) were not listed on the vaccine label (Table 3). 
In the case of children vaccinated with PPSVs, only one AE 
[increased serum glutamic oxaloacetic transaminase (SGOT) 
level] satisfied all three indices, and it was not listed on the 
vaccine label (Table 4). No AE satisfied the criteria for signal 
detection in children vaccinated with PCVs (Table 5). 
The results of validation analysis show that PRR and ROR 
had a sensitivity ranging from 0% to 40% and a specificity from 
66.7% to 100% (Table 6). IC had a sensitivity ranging from 0% 
to 36% and a specificity from 0% to 100%. For adults vaccinat-
ed with PPSVs, PRR and ROR indices performed better than 
IC, albeit slightly. However, in comparing the signals for chil-
dren, the results were not significant as there were cases of 
these indices having a value of 0.
DISCUSSION
This study represents a post-marketing safety review of pneu-
mococcal vaccines based on AE reports in KAERS database 
between 2005 and 2016. The most common AE was pharyngi-
tis in children vaccinated with PCVs and injection-site reac-
tion in adults vaccinated with PPSVs. These results were consis-
tent with the data on labels of PPSVs and PCVs.18-21 Respiratory 
Fig. 1. Trends in reported AEs after vaccination with PPSV and PCV compared to reported AEs after vaccination with all vaccines from KIDS database in 
2005–2016. AE, adverse event; PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate vaccine; KIDS, Korea Institute of Drug Safe-
ty and Risk Management.
Table 2. Comparison of Adverse Events Reported to KAERS after Receiv-









Body as a whole-general disorder
Fever 328 (18.4) 426 (23.9) 60 (12.0) <0.001
Crying abnormally 0 (0.0) 121 (6.8) 23 (4.6) 0.077
Respiratory system disorder
Pneumonia 27 (1.5) 132 (7.4) 57 (11.4) 0.006
Pharyngitis 29 (1.6) 360 (20.2) 131 (26.2) 0.005
Upper respiratory tract infection 9 (0.5) 268 (15.0) 91 (18.2) 0.095
Rhinitis 9 (0.5) 263 (14.7) 116 (23.2) <0.001
Coughing 21 (1.2) 164 (9.2) 63 (12.6) 0.028
Bronchitis 2 (0.1) 137 (7.7) 64 (12.8) 0.001
Psychiatric disorder
Nervousness 0 (0.0) 223 (12.5) 60 (12.0) 0.818
Gastro-intestinal system disorder
Vomiting 35 (2.0) 148 (8.3) 44 (8.8) 0.716
Diarrhea 30 (1.7) 120 (6.7) 49 (9.8) 0.026
Gastroenteritis 3 (0.2) 77 (4.3) 37 (7.4) 0.007
Skin and appendages disorder
Rash 66 (3.7) 78 (4.4) 20 (4.0) 0.803
Dermatitis 1 (0.1) 51 (2.9) 18 (3.6) 0.378
Application site disorder
Injection-site reaction 446 (25.0) 39 (2.2) 8 (1.6) 0.480
Resistance mechanism disorder
Otitis media 0 (0.0) 74 (4.1) 34 (6.8) 0.017
KAERS, Korea Adverse Event Reporting System; PPSV, pneumococcal poly-
saccharide vaccine; PCV, pneumococcal conjugate vaccine.


















































































2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
 % of PPSV 40.0 30.4 20.2 37.2 19.2 14.4 2.6 15.9 16.7 17.6 7.0 15.6
 % of PCV   0.0   0.0   0.0   0.0   0.0   0.3 0.6   0.7   3.0   0.7 0.9   2.6
 Number of reported AEs after all vaccines 20 46 89 196 385 631 3597 1204 10801 4861 11613 6490
 Number of reported AEs after PPSV   8 14 18   73   74   91     92   192   1808   857     817 1011
 Number of reported AEs after PCV   0   0   0     0     0     2     22       9     324     33     106   167
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disorders, such as pharyngitis and rhinitis, in children receiv-
ing PCVs were mentioned on the vaccine labels in South Ko-
rea based on reassessment results. The result that injection-
site reaction was the most frequent AE in adults after receiving 
PPSVs was consistent with the findings of previous studies.22-24 
A controlled clinical trial involving adults reported that the 
degree of injection-site pain was higher for 23-valent PPSVs 
than for 13-valent PCVs, but there was no difference in the 
percentage of systemic AEs.14 However, a safety profile com-
parison would yield different results according to research 
conditions and target patients. Our comparison of AE reports 
showed that the proportion of SAEs reported among children 
was similar for both PPSVs and PCVs. However, cases of death 
were only reported for PPSVs. In PPSV group, SAEs were re-
ported for a greater proportion of adults than that of children 
(18.1% and 7.6%, respectively). Most adults (89.2%) received 
only one vaccine whereas 56.7% and 47.8% of the children 
vaccinated with PPSVs and PCVs, respectively, received other 
Table 3. Signals of Adverse Events Related to PPSVs in Adults Aged ≥19 Years Detected by Data Mining and the Presence of Information on Vaccine 
Label, 2005–2016
     Adverse event No. of reports PRR ROR IC 95% LCI Label* Signal detection
Injection-site reaction 446 4.03 4.50 1.34 Y Y
Fever 328 3.06 3.28 1.06 Y Y
Injection-site pain 323 0.52 0.47 -1.02 Y N
Myalgia 210 0.87 0.86 -0.38 Y N
Injection-site rash 188 1.82 1.87 0.48 Y N
Cellulitis 70 15.37 15.68 1.91 Y Y
Rash 66 1.55 1.56 0.15 Y N
Rigors 61 0.89 0.88 -0.52 Y N
Rash erythematous 50 3.57 3.61 0.94 Y Y
Dizziness 48 0.76 0.75 -0.76 Y N
Headache 44 0.36 0.35 -1.74 Y N
Pain 41 0.83 0.83 -0.68 Y N
Nausea 38 0.64 0.63 -1.03 Y N
Edema 37 2.23 2.24 0.43 Y Y
Vomiting 35 0.95 0.95 -0.55 Y N
Asthenia 31 0.89 0.89 -0.65 Y N
Urticaria 30 0.85 0.85 -0.71 Y N
Dyspnea 30 1.83 1.83 0.17 N N
Injection-site mass 29 0.99 0.99 -0.53 Y N
Pneumonia 27 9.76 9.84 1.46 Y Y
Injection-site infection 24 7.38 7.42 1.27 Y Y
Allergic reaction 22 3.07 3.09 0.60 Y Y
Coughing 21 0.92 0.92 -0.70 N N
Chest pain 20 1.86 1.87 0.08 N N
Fatigue 11 0.09 0.08 -4.07 Y N
Hypotension 10 2.28 2.28 0.06 N Y
Sputum increased 7 2.15 2.15 -0.13 N N
Apathy 6 4.61 4.62 0.42 N Y
Vision abnormal 6 1.94 1.94 -0.29 N N
Conjunctivitis 5 1.54 1.54 -0.59 N N
Leukocytosis 5 7.68 7.68 0.61 Y Y
Sepsis 5 6.15 6.16 0.50 N Y
Angioedema 4 1.54 1.54 -0.67 Y N
Hyperpyrexia 4 2.46 2.46 -0.24 Y N
Neuritis 3 0.28 0.27 -2.80 N N
Urine abnormal 1 3.07 3.07 -0.66 N N
Breast pain 1 3.07 3.07 -0.66 N N
PPSVs, pneumococcal polysaccharide vaccines; PRR, proportional reporting ratio; ROR, reporting odds ratio; IC 95% LCI, information component lower limit of 
95% confidence interval.
*Y: AE was listed on the vaccine label, N: AE was not listed on the vaccine label.
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Table 4. Signals of Adverse Events Related to PPSVs for Children Aged 0–18 Years Detected by Data Mining and the Presence of Information on Vac-
cine Label, 2005–2016
       Adverse event No. of reports PRR ROR IC 95% LCI Label* Signal detection
Fever 426 1.32 1.36 0.17 Y N
Diarrhea 120 1.20 1.21 -0.06 N N
Rash 78 1.41 1.41 0.06 Y N
Conjunctivitis 33 1.57 1.58 0.01 N N
Injection-site infection 26 0.72 0.72 -0.95 Y N
Urinary tract infection 25 1.23 1.23 -0.32 N N
Injection-site pain 8 0.08 0.07 -4.31 Y N
Infection viral 7 0.76 0.76 -1.26 N N
Melaena 6 1.48 1.48 -0.58 N N
Cellulitis 4 0.59 0.59 -1.75 Y N
SGOT increased 3 16.28 16.29 0.43 N Y
Hyperpyrexia 3 0.32 0.32 -2.59 Y N
Intestinal obstruction 2 0.78 0.78 -1.63 N N
Enterocolitis 2 2.71 2.71 -0.53 N N
Bradycardia 1 2.71 2.71 -0.82 N N
SGPT increased 1 5.43 5.43 -0.54 N N
Apnea 1 1.81 1.81 -1.05 N N
Respiratory insufficiency 1 5.43 5.43 -0.54 N N
PPSVs, pneumococcal polysaccharide vaccines; PRR, proportional reporting ratio; ROR, reporting odds ratio; IC 95% LCI, information component lower limit of 
95% confidence interval; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
*Y: AE was listed on the vaccine label, N: AE was not listed on vaccine label.
Table 5. Signals for Adverse Events of PCVs in Children Aged 0–18 Years Detected by Data Mining and the Presence of Information on Vaccine Label, 
2005–2016
    Adverse event No. of reports PRR ROR IC 95% LCI Label* Signal detection
Fever 60   0.57 0.55 -1.14 Y N
Skin disorder   4   1.26 1.26 -0.72 Y N
Rash erythematous   3   0.36 0.36 -2.49 Y N
Sweet’s syndrome   2 20.17 20.2  1.56 N N
PCVs, pneumococcal conjugate vaccines; PRR, proportional reporting ratio; ROR, reporting odds ratio; IC 95% LCI, information component lower limit of 95% confi-
dence interval.
*Y: AE was listed on the vaccine label, N: AE was not listed on vaccine label. 
Table 6. Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value for Each Index Following PPSV in Adults Aged ≥19 Years, and 
PPSV and PCV in Children aged 0–18 Years, 2005–2016.
Vaccine Index
Known AEs







Yes 10   4
40.0   66.7   71.4 34.8
No 15   8
IC
Yes   9   5
36.0   58.3   64.3 30.4
No 16   7
PPSV in children
PRR, ROR
Yes   0   1
  0.0   91.7     0.0 64.7
No   6 11
IC
Yes   2   0
33.3 100.0 100.0 73.3
No   4 11
PCV in children
PRR, ROR
Yes   0   0
  0.0 100.0 N/A 25.0
No   3   1
IC
Yes   0   1
  0.0     0.0     0.0   0.0
No   3   0
PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate vaccine; AE, adverse event; PRR, proportional reporting ratio; ROR, reporting odds 
ratio; IC 95% LCI, information component lower limit of 95% confidence interval; N/A, not applicable.
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vaccines. Nonetheless, the percentage of AEs, for which the 
degree of causality was assessed to be more than possible, 
was higher for adults than for children. Our findings suggest 
that SAEs after pneumococcal vaccination are more frequent 
and probably more causal in adults than in children. 
We identified 13 new signals for which all three of the data 
mining methods used (PRR, ROR, and IC) indicated signifi-
cant results. Among these, four AEs (hypotension, apathy, sep-
sis, and increased SGOT level) after PPSV administration were 
not listed in the approved label. Hypotension and apathy after 
receiving PPSV have not been reported in South Korea or else-
where, suggesting the need for further studies. Several cases 
of sepsis were reported after pneumococcal vaccination; how-
ever, they were presumed to have been caused not by the vac-
cination itself, but by the weakened immunity of the patients.25 
Our finding of increased SGOT level was consistent with the 
finding of a previous study, which showed that elevated C-re-
active protein level after vaccination may cause an increase in 
the serum level of hepatic enzymes.26 According to the results 
of our validation analysis, PRR and ROR were slightly better 
than IC for adults vaccinated with PPSVs. The same results 
could not be obtained for children due to the existence of 0 val-
ues for these indices in some cases. A future study with more 
cases is needed to determine which indicator is appropriate for 
signal detection in children. 
In our data, pneumonia was reported in both adults and 
children who were vaccinated with pneumococcal vaccines. 
Although the labels of pneumococcal vaccines list pneumo-
nia as one of the AEs, they only refer to pneumonia caused by 
serotypes that are not included in the vaccine. The actual case 
of compensation for the occurrence of pneumonia was reject-
ed since the vaccine did not cause systemic infections.27 There-
fore, in order to establish the causality between pneumococcal 
vaccination and pneumonia, recipients experiencing pneu-
monia after vaccination should be followed up for serological 
studies. 
To date, there has been no epidemiological study on AEs 
due to pneumococcal vaccinations in South Korea. To the best 
of our knowledge, this study is the first to detect signals of AEs 
after pneumococcal vaccinations by mining KAERS data. The 
KAERS database contains AE data and reassessment results 
collected from 27 local monitoring centers in South Korea. In 
order to increase the rigor of the current study, we used three 
different data mining methods to detect and validate signals 
after pneumococcal vaccinations. Due to these strengths, the 
findings of this study may be useful for analyzing post-mar-
keting AEs of pneumococcal vaccines. 
However, this study had a few limitations. The limitations 
with spontaneous reporting data used in this study include 
underreporting, inconsistent quality of reports (for example, 
reports may lack details and important information or contain 
errors), and the lack of non-vaccinated control groups.28 Fur-
thermore, the data we used did not provide information about 
other underlying diseases affecting patients or their recovery 
from SAEs. Therefore, additional studies, including literature 
reviews, randomized clinical trials, and cohort studies, are re-
quired to assess the causality. Moreover, KAERS data did not 
provide the specific brand names of the vaccines. As a result, 
AE data were analyzed based on vaccine type (PPSVs and PCVs) 
only. Finally, although PCVs are currently used for both adults 
and children, we could not compare the safety profiles of PCVs 
between adults and children, since only a single case of AE in 
an adult after receiving PCV was reported in 2016. Further re-
search based on recent data is required to compare the AEs 
between children and adults after receiving PCVs. Even for 
children who received PCVs, no significant difference was ob-
served between signal information obtained from our data and 
the approved label. Addressing the deficiencies highlighted in 
this study could lead to better management of AE cases in the 
future.
In conclusion, we identified 13 new signals of PPSVs for 
which all three data mining methods of PRR, ROR, and IC in-
dicated significant results. Among these, four signals (i.e., hy-
potension, apathy, sepsis, and increased SGOT level) were 
not listed in the approved vaccine label. The results of our val-
idation analysis showed that PRR and ROR were slightly better 
than IC for adults vaccinated with PPSVs, although the same 
results could not be obtained in children. A future study based 
on a larger number of AE reports is needed to confirm the va-
lidity of the detected signals for children receiving pneumo-
coccal vaccination.
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